详细记录  
题名:Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration
作者:Holger K. de Wolf, Cor J. Snel, Ferry J. Verbaan, Raymond M. Schiffelers, Wim E. Hennink and Gert Storm
来源:International Journal of Pharmaceutics[IF=2.156], Volume 331, Issue 2, 1 March 2007, Pages 167-175
URL :http://dx.doi.org/10.1016/j.ijpharm.2006.10.029
日期:070415
摘要: Holger K. de Wolf1, a, Cor J. Snel1, a, Ferry J. Verbaan1, a, Raymond M. Schiffelers1, a, Wim E. Hennink1, a and Gert Storm, a,

aDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands

Received 3 August 2006; revised 26 September 2006; accepted 9 October 2006. Available online 26 October 2006.

Summary

Nucleic acid based therapeutics are currently being studied for their application in cancer therapy. In this study, the effect of different cationic delivery systems on the circulation kinetics, tumor localization, and tissue distribution of short interfering RNA (siRNA) and plasmid DNA (pDNA) was examined, after intravenous administration in mice bearing a s.c. Neuro 2A tumor. Nanosized particles were formed upon complexation of siRNA with the cationic liposome formulation DOTAP/DOPE and the targeted, cationic polymer RGD-PEG-PEI. Both the circulation kinetics and the overall tumor localization of the siRNA complexes were similar to non-complexed siRNA. Importantly, the different carriers changed the intratumoral distribution of siRNA within the tumor. pDNA was effectively condensed with linear polyethylenimine (PEI), PEGylated linear PEI (PEG-PEI) or poly(2-dimethylamino ethylamino)phosphazene. Only PEG-PEI was able to improve the pDNA circulation kinetics. All pDNA complexes yielded similar pDNA tumor localization (1% of the injected dose, 60 min after administration). We conclude that the level of nucleic acid tumor localization is independent on the type of formulation used in this study. Therefore, the value of carrier systems for the intravenous delivery of nucleic acids cannot be solely attributed to benefits relevant during the transport towards the tumor. Rather, the benefits are arising from carrier-induced changes in the intratumoral fate of the nucleic acids. 20.

================  评  论  部  分=================

重要性:
分类:(参照 Faculty of 1000 的分类体系)


评语:

评论密码:   返回前页  [全部]